(Q30369841)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542759%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

title

Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: Time to write the obituary? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542759%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

0 references

Malcolm J Moore

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542759%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

1 March 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542759%20AND%20SRC:MED&resulttype=core&format=json

Canadian Urological Association journal

8 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542759%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542759%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542759%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542759%20AND%20SRC:MED&resulttype=core&format=json

Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: a systematic review and practice guideline.

8 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2422916

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2422916

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2422916

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2422916

26 November 2018

Identifiers

DOI

10.5489/CUAJ.36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542759%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542759%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

PubMed publication ID

18542759

1 reference